Vanda Pharmaceuticals Inc. (VNDA)

13.69
NASDAQ : Health Technology
Prev Close 13.64
Day Low/High 13.67 / 13.96
52 Wk Low/High 11.83 / 33.44
Avg Volume 700.00K
Exchange NASDAQ
Shares Outstanding 53.27M
Market Cap 723.99M
EPS 0.50
P/E Ratio 25.74
Div & Yield N.A. (N.A)

Latest News in Activist Investing

Activist investors are clamoring for change at companies such as AP Pharma and Lions Gate.

This Week's 'Barron's' Roundup

This Week's 'Barron's' Roundup

The latest dividend changes, and going bullish on Northern Trust and Hewlett-Packard.

Biotech Mailbag 2008 Review

Here's a look back at the hits, misses and notable moments from 2008.

Feuerstein's Biotech-Stock Mailbag: Titan

Feuerstein's Biotech-Stock Mailbag: Titan

Why Titan Pharma needs a development partner. And disparate outlooks for Gilead, Vanda and YM BioSciences.

Feuerstein's Biotech-Stock Mailbag: Elan

Feuerstein's Biotech-Stock Mailbag: Elan

Revaluing a severely beaten Elan. And wanted: Your votes on best biotech CEO.

Health Winners & Losers: Amgen

Health Winners & Losers: Amgen

Amgen climbs on phase III study results of denosumab.

Vanda Sinks on FDA Rejection (Update)

Vanda Sinks on FDA Rejection (Update)

Its lead drug, antipsychotic iloperidone, will require another clinical trial and more safety data before approval.

Vanda Pharma Sinks on FDA Rejection

Vanda Pharma Sinks on FDA Rejection

Its lead drug, antipsychotic iloperidone, will require another clinical trial and more safety data before approval.

Vanda Sleep Drug Data Sedate Investors

A late-stage study of tasimelte meets its primary endpoint but not secondary ones related to sleep maintenance.

Biotech-Stock Mailbag: Sangamo

Biotech-Stock Mailbag: Sangamo

Weighing chances for Sangamo's lead pipeline drug, and more.

Biotech Notebook: Vertex, Medicines Co.

Biotech Notebook: Vertex, Medicines Co.

Uncertain regulation hangs on Vertex's telaprevir, The Medicines Co. remains mum on Cleviprex and a summer biotech-stock watch list.

Health Winners & Losers: Tercica

Health Winners & Losers: Tercica

Tercica soars on news of a $663 million buyout.

Friday's Winners & Losers: Yahoo!

Friday's Winners & Losers: Yahoo!

Shares rise 6.9% on more merger rumors.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Discovery Labs falls on another regulatory delay for its Surflaxin.

Feuerstein's Biotech-Stock Mailbag

BioSante Pharma's chief takes on the critics.

Feuerstein's Biotech Mailbag

Feuerstein's Biotech Mailbag

This week, Adam responds to reader inquiries about Xoma, Vanda and Onyx.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

QLT climbs on news it's looking into 'strategic alternatives.'

Thursday's Health Winners & Losers

Pozen rises.

Thursday's Small-Cap Winners & Losers

Thursday's Small-Cap Winners & Losers

Flotek sinks.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Celera rises.

Vanda Rises on Offering

It raises $96 million.

Markets Break for Jobs

Markets Break for Jobs

Markets dip as traders await a crucial jobs report.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Tercica jumps.

Vanda Surges on Study Results

The update is on experimental antipsychotic drug iloperidone.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Vanda Pharmaceuticals soars.

Wednesday's Small-Cap Winners & Losers

Wednesday's Small-Cap Winners & Losers

Vanda Pharma shares rise more than 35% on positive trial data for its insomnia treatment.

Vanda Vaults on Study Results

Vanda Vaults on Study Results

The stock surges nearly 60%.

Today's Health Winners and Losers

Today's Health Winners and Losers

Two biopharmaceutical IPOs fall on their first day of trading.

TheStreet Quant Rating: C (Hold)